Bain Capital Public Equity Management Ii, LLC Dynavax Technologies Corp Transaction History

Bain Capital Public Equity Management Ii, LLC

$1.99 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$9.16 - $19.83 $2.01 Million - $4.36 Million	-219,800 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$7.25 - $10.99 $587,250 - $890,190	-81,000 Reduced 26.93%	219,800 $2.17 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $11.18 $785,528 - $1.92 Million	171,888 Added 133.34%	300,800 $2.96 Million
Q3 2020 Nov 16, 2020	SELL	$4.32 - $11.7 $3.35 Million - $9.07 Million	-775,567 Reduced 85.75%	128,912 $557,000
Q2 2020 Aug 14, 2020	SELL	$2.94 - $9.1 $5.81 Million - $18 Million	-1,977,557 Reduced 68.62%	904,479 $8.03 Million
Q1 2020 May 15, 2020	SELL	$2.27 - $6.2 $1.54 Million - $4.2 Million	-677,511 Reduced 19.03%	2,882,036 $10.2 Million
Q4 2019 Feb 14, 2020	BUY	$3.46 - $6.93 $741,135 - $1.48 Million	214,201 Added 6.4%	3,559,547 $20.4 Million
Q3 2019 Feb 12, 2020	SELL	$2.69 - $4.85 $3.9 Million - $7.03 Million	-1,450,000 Reduced 30.24%	3,345,346 $12 Million
Q3 2019 Nov 14, 2019	BUY	$2.69 - $4.85 $9.39 Million - $16.9 Million	3,490,000 Added 267.36%	4,795,346 $15.1 Million
Q2 2019 Aug 14, 2019	BUY	$3.65 - $7.89 $4.76 Million - $10.3 Million	1,305,346 New	1,305,346 $5.21 Million

Others Institutions Holding DVAX

# of Institutions

275

Shares Held

130M

Call Options Held

451K

Put Options Held

203K

Black Rock Inc. New York, NY

21.9M
Shares

$279 Million
0.01% of portfolio
Deep Track Capital, LP Greenwich, CT

12.5M
Shares

$159 Million
5.15% of portfolio
Vanguard Group Inc Valley Forge, PA

9.22M
Shares

$117 Million
0.0% of portfolio
Kynam Capital Management, LP Princeton, NJ

8.33M
Shares

$106 Million
7.62% of portfolio
State Street Corp Boston, MA

7.69M
Shares

$97.8 Million
0.0% of portfolio

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.61B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Account